NICE Approves Combo Therapy for Leukemia by J&J and Abbvie

The UK’s National Institute of Health and Care Excellence (NICE) has issued its approval of J&J and Abbvie’s combination therapy of Imbruvica and Venclyxto for use as a first-line treatment of chronic lymphocytic leukemia (CLL). The combo will be released as a pill taken once per day, the first of its kind for a CLL chemotherapy drug.

According to Phil Taylor, “In its appraisal document, NICE said that ibrutinib plus venetoclax’s fixed treatment duration and better toxicity profile than current treatments made it a ‘highly valued treatment option.’”

To read more, click here.

(Source: Pharmaphorum, April 21^st, 2023)